Advertisement

Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”

Published:November 13, 2022DOI:https://doi.org/10.1016/j.ejca.2022.10.007
      In a phase 3, multicentre, open-label, randomised trial, trastuzumab deruxtecan (TD) was superior to the standard of care trastuzumab emtansine in patients with HER2-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane [
      • Cortés J.
      • Kim S.B.
      • Chung W.P.
      • Im S.A.
      • Park Y.H.
      • Hegg R.
      • et al.
      DESTINY-Breast03 trial investigators. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.
      ]. Then, a phase 3 trial with HER2-low mBC patients (defined as 1+ and 2+ by immunohistochemistry [IHC] or negative by in situ hybridisation [ISH]) who had received previous lines of chemotherapy was performed [
      • Modi S.
      • Jacot W.
      • Yamashita T.
      • Sohn J.
      • Vidal M.
      • Tokunaga E.
      • et al.
      Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
      ]. In this trial TD resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cortés J.
        • Kim S.B.
        • Chung W.P.
        • Im S.A.
        • Park Y.H.
        • Hegg R.
        • et al.
        DESTINY-Breast03 trial investigators. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.
        N Engl J Med. 2022 Mar 24; 386 (PMID:35320644): 1143-1154https://doi.org/10.1056/NEJMoa2115022
        • Modi S.
        • Jacot W.
        • Yamashita T.
        • Sohn J.
        • Vidal M.
        • Tokunaga E.
        • et al.
        Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
        N Engl J Med. 2022 Jul 7; 387 (Epub 2022 Jun 5. PMID:35665782): 9-20https://doi.org/10.1056/NEJMoa2203690
        • Venetis K.
        • Crimini E.
        • Sajjadi E.
        • Corti C.
        • Guerini-Rocco E.
        • Viale G.
        • et al.
        HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer.
        Front Mol Biosci. 2022 Mar; 15 (eCollection 2022.PMID:35372498): 834651https://doi.org/10.3389/fmolb.2022.834651
        • Van Raemdonck E.
        • Floris G.
        • Berteloot P.
        • Laenen A.
        • Vergote I.
        • Wildiers H.
        • Punie K.
        • Neven P.
        Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
        Breast Cancer Res Treat. 2021 Jan; 185 (Epub 2020 Sep 27.PMID: 32980945): 183-194https://doi.org/10.1007/s10549-020-05935-5
        • Walter V.
        • Fischer C.
        • Deutsch T.M.
        • Ersing C.
        • Nees J.
        • Schütz F.
        • Fremd C.
        • Grischke E.M.
        • Sinn P.
        • Brucker S.Y.
        • Schneeweiss A.
        • Hartkopf A.D.
        • Wallwiener M.
        Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
        Breast Cancer Res Treat. 2020 Aug; 183 (Epub 2020 Jul 1. PMID: 32613540): 137-144https://doi.org/10.1007/s10549-020-05746-8
        • Tarantino P.
        • Gandini S.
        • Nicolò E.
        • Trillo P.
        • Giugliano F.
        • Zagami P.
        • et al.
        Evolution of low HER2 expression between early and advanced-stage breast cancer.
        Eur J Cancer. 2022; 163 (Epub 2022 Jan 13. PMID:35032815): 35-43https://doi.org/10.1016/j.ejca.2021.12.022
        • Tarantino P.
        • Hamilton E.
        • Tolaney S.M.
        • Cortes J.
        • Morganti S.
        • Ferraro E.
        • et al.
        HER2-Low breast cancer: pathological and clinical landscape.
        J Clin Oncol. 2020; 38 (10) (Epub 2020 Apr 24. PMID:32330069): 1951-1962https://doi.org/10.1200/JCO.19.02488

      Linked Article